IBCN 2018: STAG2 Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle Invasive Bladder Cancer

Rotterdam, The Netherlands (UroToday.com) Alana Lelo a fifth-year Tumor Biology MD/ Ph.D. student discussed her team's STAG2 biomarker validation study using two independent cohorts of clinically-annotated papillary non muscle-invasive bladder cancer (NMIBC) tumors from the US and Europe.

The value of STAG2 immunostaining for prediction of recurrence was initially evaluated in a cohort of 82 patients with papillary NMIBC (“Georgetown cohort”). Next, the value of STAG2 immunostaining for prediction of progression to muscle invasion was evaluated in a progressor-enriched cohort of 253 patients with papillary NMIBC (“Aarhus cohort”).

In the Georgetown cohort, 52% of NMIBC tumors with intact STAG2 expression recurred, whereas 25% of STAG2-deficient tumors recurred (p=0.02). Multivariable analysis identified STAG2 expression as an independent predictor of recurrence (HR=2.4; p=0.05). In the progressor-enriched Aarhus cohort, 38% of tumors with intact STAG2 expression progressed within five years, versus 16% of STAG2-deficient tumors (p<0.01). Multivariable analysis identified intact STAG2 expression as an independent predictor of progression (HR=1.86; p=0.05). STAG2 IHC is a simple, binary, new assay for risk stratification in papillary NMIBC.

These findings provide another biomarker (STAG2), which now has been validated in 2 cohorts and may further aid in risk stratification in papillary NMIBC.


Presented by: Alana Lelo, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC

Co-Authors: Frederik Prip 5, Brent T. Harris3,4, David Solomon6, Deborah L. Berry1,4, Krysta Chaldekas4, Anagha Kumar7, Jeffry Simko6, Jørgen Bjerggaard Jensen8 , Pritish Bhattacharyya9, Ciaran Mannion9, Jung-Sik Kim1, George Philips1,10, Lars Dyrskjøt 5, Todd Waldman1
Author Affiliation: 
1. Departments of Oncology, Tumor Biology Training Program, Pathology
4. Histopathology and Tissue Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 
5. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
6. Department of Pathology, University of California San Francisco School of Medicine, San Francisco, CA 
7. Department of Biostatistics, MedStar Health Research Institute, Washington, DC 
8. Department of Urology, Aarhus University Hospital, Aarhus, Denmark 
9. Department of Pathology, Hackensack University Medical Center, Hackensack, NJ 
10. MedStar Washington Hospital Center

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 16th Annual Meeting of the International Bladder Cancer Network (IBCN) October 11-13, 2018 - the Inntel Hotels Rotterdam Centre, Rotterdam, The Netherlands
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe